Early postoperative intraperitoneal chemotherapy following cytoreductive surgery in patients with very advanced gastric cancer

Jae Ho Cheong, Jia Yun Shen, Chang Soo Song, Woo Jin Hyung, Jian Guo Shen, Seung Ho Choi, Sung Hoon Noh

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: The survival of patients with stage IV gastric cancer is poor due to frequent peritoneal failure. The aim of this study was to investigate the impact of early postoperative intraperitoneal chemotherapy (EPIC) after cytoreductive surgery on the long-term survival of these patients, as determined by residual disease status. Methods: A total of 154 patients with stage IV gastric cancer were enrolled in our study. All patients underwent potentially curative or palliative resections. After surgery, the residual disease states of the patients were recorded. All patients received EPIC. Results: Of all 154 patients, R0 resection was achieved in 37, R1 in 56, and R2 in 61. All patients received a mean of 4.3 EPIC perfusions. After a mean followup period of 29 months, 14 patients remained alive. The median survival of all 154 patients was 11.4 months. Survival times were analyzed according to the type of residual tumor; the median survival time was 25.5 months in the R0 group, 15.6 months in the R1 group, and 7.2 months in the R2 group (p < .001). Upon multivariate analysis, the residual tumor states and the cycle of EPIC perfusion were found to be independent prognostic predictors (p < .001 and p = .018, respectively). Conclusions: The residual tumor status is the most important predictor for the survival of very advanced gastric cancer patients who received cytoreductive surgery and EPIC. Therefore, complete cytoreductive surgery yielding R0 resection is mandatory for achieving the beneficial effects of EPIC.

Original languageEnglish
Pages (from-to)61-68
Number of pages8
JournalAnnals of surgical oncology
Volume14
Issue number1
DOIs
Publication statusPublished - 2007 Jan 1

Fingerprint

Stomach Neoplasms
Drug Therapy
Survival
Residual Neoplasm
Perfusion
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Cheong, Jae Ho ; Shen, Jia Yun ; Song, Chang Soo ; Hyung, Woo Jin ; Shen, Jian Guo ; Choi, Seung Ho ; Noh, Sung Hoon. / Early postoperative intraperitoneal chemotherapy following cytoreductive surgery in patients with very advanced gastric cancer. In: Annals of surgical oncology. 2007 ; Vol. 14, No. 1. pp. 61-68.
@article{b561f8159c1a468795da2b719ff44853,
title = "Early postoperative intraperitoneal chemotherapy following cytoreductive surgery in patients with very advanced gastric cancer",
abstract = "Background: The survival of patients with stage IV gastric cancer is poor due to frequent peritoneal failure. The aim of this study was to investigate the impact of early postoperative intraperitoneal chemotherapy (EPIC) after cytoreductive surgery on the long-term survival of these patients, as determined by residual disease status. Methods: A total of 154 patients with stage IV gastric cancer were enrolled in our study. All patients underwent potentially curative or palliative resections. After surgery, the residual disease states of the patients were recorded. All patients received EPIC. Results: Of all 154 patients, R0 resection was achieved in 37, R1 in 56, and R2 in 61. All patients received a mean of 4.3 EPIC perfusions. After a mean followup period of 29 months, 14 patients remained alive. The median survival of all 154 patients was 11.4 months. Survival times were analyzed according to the type of residual tumor; the median survival time was 25.5 months in the R0 group, 15.6 months in the R1 group, and 7.2 months in the R2 group (p < .001). Upon multivariate analysis, the residual tumor states and the cycle of EPIC perfusion were found to be independent prognostic predictors (p < .001 and p = .018, respectively). Conclusions: The residual tumor status is the most important predictor for the survival of very advanced gastric cancer patients who received cytoreductive surgery and EPIC. Therefore, complete cytoreductive surgery yielding R0 resection is mandatory for achieving the beneficial effects of EPIC.",
author = "Cheong, {Jae Ho} and Shen, {Jia Yun} and Song, {Chang Soo} and Hyung, {Woo Jin} and Shen, {Jian Guo} and Choi, {Seung Ho} and Noh, {Sung Hoon}",
year = "2007",
month = "1",
day = "1",
doi = "10.1245/s10434-006-9205-7",
language = "English",
volume = "14",
pages = "61--68",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "1",

}

Early postoperative intraperitoneal chemotherapy following cytoreductive surgery in patients with very advanced gastric cancer. / Cheong, Jae Ho; Shen, Jia Yun; Song, Chang Soo; Hyung, Woo Jin; Shen, Jian Guo; Choi, Seung Ho; Noh, Sung Hoon.

In: Annals of surgical oncology, Vol. 14, No. 1, 01.01.2007, p. 61-68.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Early postoperative intraperitoneal chemotherapy following cytoreductive surgery in patients with very advanced gastric cancer

AU - Cheong, Jae Ho

AU - Shen, Jia Yun

AU - Song, Chang Soo

AU - Hyung, Woo Jin

AU - Shen, Jian Guo

AU - Choi, Seung Ho

AU - Noh, Sung Hoon

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Background: The survival of patients with stage IV gastric cancer is poor due to frequent peritoneal failure. The aim of this study was to investigate the impact of early postoperative intraperitoneal chemotherapy (EPIC) after cytoreductive surgery on the long-term survival of these patients, as determined by residual disease status. Methods: A total of 154 patients with stage IV gastric cancer were enrolled in our study. All patients underwent potentially curative or palliative resections. After surgery, the residual disease states of the patients were recorded. All patients received EPIC. Results: Of all 154 patients, R0 resection was achieved in 37, R1 in 56, and R2 in 61. All patients received a mean of 4.3 EPIC perfusions. After a mean followup period of 29 months, 14 patients remained alive. The median survival of all 154 patients was 11.4 months. Survival times were analyzed according to the type of residual tumor; the median survival time was 25.5 months in the R0 group, 15.6 months in the R1 group, and 7.2 months in the R2 group (p < .001). Upon multivariate analysis, the residual tumor states and the cycle of EPIC perfusion were found to be independent prognostic predictors (p < .001 and p = .018, respectively). Conclusions: The residual tumor status is the most important predictor for the survival of very advanced gastric cancer patients who received cytoreductive surgery and EPIC. Therefore, complete cytoreductive surgery yielding R0 resection is mandatory for achieving the beneficial effects of EPIC.

AB - Background: The survival of patients with stage IV gastric cancer is poor due to frequent peritoneal failure. The aim of this study was to investigate the impact of early postoperative intraperitoneal chemotherapy (EPIC) after cytoreductive surgery on the long-term survival of these patients, as determined by residual disease status. Methods: A total of 154 patients with stage IV gastric cancer were enrolled in our study. All patients underwent potentially curative or palliative resections. After surgery, the residual disease states of the patients were recorded. All patients received EPIC. Results: Of all 154 patients, R0 resection was achieved in 37, R1 in 56, and R2 in 61. All patients received a mean of 4.3 EPIC perfusions. After a mean followup period of 29 months, 14 patients remained alive. The median survival of all 154 patients was 11.4 months. Survival times were analyzed according to the type of residual tumor; the median survival time was 25.5 months in the R0 group, 15.6 months in the R1 group, and 7.2 months in the R2 group (p < .001). Upon multivariate analysis, the residual tumor states and the cycle of EPIC perfusion were found to be independent prognostic predictors (p < .001 and p = .018, respectively). Conclusions: The residual tumor status is the most important predictor for the survival of very advanced gastric cancer patients who received cytoreductive surgery and EPIC. Therefore, complete cytoreductive surgery yielding R0 resection is mandatory for achieving the beneficial effects of EPIC.

UR - http://www.scopus.com/inward/record.url?scp=33845683034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845683034&partnerID=8YFLogxK

U2 - 10.1245/s10434-006-9205-7

DO - 10.1245/s10434-006-9205-7

M3 - Article

C2 - 17058123

AN - SCOPUS:33845683034

VL - 14

SP - 61

EP - 68

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 1

ER -